Nektar Therapeutics (NKTR) PT Set at $45.00 by Roth Capital

Nektar Therapeutics (NASDAQ:NKTR) has been assigned a $45.00 price target by equities researchers at Roth Capital in a research report issued on Monday. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Roth Capital’s target price suggests a potential upside of 13.75% from the company’s previous close.

NKTR has been the subject of several other reports. Jefferies Group LLC reiterated a “buy” rating and issued a $23.00 target price on shares of Nektar Therapeutics in a report on Friday, July 21st. Cowen and Company began coverage on shares of Nektar Therapeutics in a report on Tuesday, November 7th. They issued an “outperform” rating for the company. Canaccord Genuity started coverage on shares of Nektar Therapeutics in a report on Thursday, November 9th. They issued a “buy” rating and a $35.00 target price for the company. BidaskClub cut shares of Nektar Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, August 4th. Finally, Evercore ISI started coverage on shares of Nektar Therapeutics in a report on Thursday, August 17th. They set an “in-line” rating and a $20.00 price target for the company. One research analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have assigned a buy rating to the company. Nektar Therapeutics currently has an average rating of “Buy” and a consensus price target of $32.91.

Nektar Therapeutics (NASDAQ NKTR) opened at $39.56 on Monday. Nektar Therapeutics has a fifty-two week low of $11.41 and a fifty-two week high of $41.34. The company has a current ratio of 4.14, a quick ratio of 3.99 and a debt-to-equity ratio of 2.91.

Nektar Therapeutics (NASDAQ:NKTR) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.37 EPS for the quarter, topping the consensus estimate of $0.21 by $0.16. Nektar Therapeutics had a negative net margin of 42.08% and a negative return on equity of 190.68%. The company had revenue of $152.90 million during the quarter, compared to analysts’ expectations of $126.50 million. During the same period last year, the company posted ($0.32) earnings per share. The business’s revenue for the quarter was up 321.2% on a year-over-year basis. sell-side analysts expect that Nektar Therapeutics will post -0.78 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Nektar Therapeutics (NKTR) PT Set at $45.00 by Roth Capital” was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international copyright law. The original version of this piece of content can be viewed at https://sportsperspectives.com/2017/11/15/nektar-therapeutics-nktr-pt-set-at-45-00-by-roth-capital.html.

In other Nektar Therapeutics news, SVP Maninder Hora sold 5,117 shares of Nektar Therapeutics stock in a transaction that occurred on Monday, November 6th. The shares were sold at an average price of $25.07, for a total value of $128,283.19. Following the completion of the sale, the senior vice president now directly owns 52,016 shares in the company, valued at $1,304,041.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Stephen K. Doberstein sold 396,323 shares of Nektar Therapeutics stock in a transaction that occurred on Wednesday, November 8th. The shares were sold at an average price of $29.00, for a total transaction of $11,493,367.00. Following the completion of the sale, the senior vice president now owns 52,016 shares of the company’s stock, valued at $1,508,464. The disclosure for this sale can be found here. Insiders sold 925,517 shares of company stock valued at $24,062,547 over the last quarter. Corporate insiders own 5.44% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. Granahan Investment Management Inc. MA raised its position in shares of Nektar Therapeutics by 5.4% in the third quarter. Granahan Investment Management Inc. MA now owns 483,800 shares of the biopharmaceutical company’s stock valued at $11,611,000 after purchasing an additional 24,599 shares during the period. Janus Henderson Group PLC raised its position in shares of Nektar Therapeutics by 87.8% in the third quarter. Janus Henderson Group PLC now owns 3,329,281 shares of the biopharmaceutical company’s stock valued at $79,903,000 after purchasing an additional 1,556,352 shares during the period. Oppenheimer Asset Management Inc. bought a new position in shares of Nektar Therapeutics in the third quarter valued at approximately $129,000. First Republic Investment Management Inc. raised its position in shares of Nektar Therapeutics by 23.6% in the third quarter. First Republic Investment Management Inc. now owns 25,864 shares of the biopharmaceutical company’s stock valued at $620,000 after purchasing an additional 4,938 shares during the period. Finally, Allianz Asset Management GmbH raised its position in shares of Nektar Therapeutics by 7.4% in the third quarter. Allianz Asset Management GmbH now owns 108,409 shares of the biopharmaceutical company’s stock valued at $2,602,000 after purchasing an additional 7,507 shares during the period. 94.97% of the stock is currently owned by institutional investors.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Analyst Recommendations for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply